Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and Healthways Editor Note: For more information about this release, please scroll to bottom. PR Newswire New York, December 13, 2013 New York, December 13, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Hologic Inc. (NASDAQ: HOLX), IDEXX Laboratories, Inc. (NASDAQ: IDXX), Endologix Inc. (NASDAQ: ELGX) and Healthways Inc. (NASDAQ: HWAY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Questcor Pharmaceuticals, Inc. Research Report On December 9, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced its partnership with the Child Neurology Foundation (CNF) for supporting the 5^th annual Infantile Spasms Awareness Week, which is being held this week. Questcor stated that as part of this education effort, CNF has developed a website that offers information on Infantile Spasms from leading child neurologists and shares stories from families dealing with this condition. Steve Cartt, Chief Operating Officer for Questcor, commented, "Questcor is privileged to continue its five-year partnership with the Child Neurology Foundation. The goal of Infantile Spasms Awareness Week is to provide pediatricians, child neurologists, parents, and caregivers with objective educational tools which will help increase awareness and understanding of this very rare form of epilepsy." According to the Company, CNF announced that Dr. Carolina Amador and the staff at Lincoln Health Center in Corvallis, Oregon, have been chosen as Infantile Spasms Hero for 2013. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/a415_QCOR Hologic Inc. Research Report On December 9, 2013, Hologic Inc. (Hologic) announced that it has appointed Jonathan Christodoro and Samuel Merksamer to the Company's Board of Directors, with immediate effect in accordance with a settlement agreement with Carl C. Icahn. The Company informed that Mr. Christodoro and Mr. Merksamer are Managing Directors of Icahn Capital LP, a subsidiary of Icahn Enterprises L.P. Hologic stated that as a result of these additions, the Company's Board now comprises of 11 directors, out of which 10 are independent. Hologic added that it has engaged Dr. Burton Drayer, Chairman and Director of the Department of Radiology at The Mount Sinai Medical Center, as a scientific advisor to the Company. In a separate press release on the same day, the Company announced that Stephen MacMillan has been named President and CEO of Hologic and a member of its Board of Directors. Hologic stated that Mr. MacMillan succeeds Jack W. Cumming. The Full Research Report on Hologic Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d132_HOLX IDEXX Laboratories, Inc. Research Report On December 6, 2013, IDEXX Laboratories, Inc. (IDEXX) announced EliteVision Digital Imaging System as the latest addition to its line of digital imaging products, designed specifically for equine veterinarians. According to the Company, the new DR system is fast and wireless, with state-of-the-art cesium technology and ImageSuite software, and offers a comprehensive patient view which allows equine veterinarians to provide their clients with advanced diagnostic services in the clinic or from the field. The Full Research Report on IDEXX Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/bf62_IDXX Endologix Inc. Research Report On December 5, 2013, Endologix Inc. (Endologix) announced the pricing of its public offering of $75 million aggregate principal amount of convertible senior notes due 2018 (the Convertible Notes). The Company informed that it has granted an option to the underwriters for up to an additional $11.25 million aggregate principal amount of Convertible Notes solely to cover overallotments. Endologix stated that the Convertible Notes will pay semiannual interest of 2.25% and will be convertible into shares of the Company's common stock, cash or a combination of cash and shares of the Company's common stock, at the Company's election, based on the applicable conversion rate at such time. The Company said that the Convertible Notes will mature on December 15, 2018, unless repurchased, redeemed or converted in accordance with their terms prior to such date. Endologix added that before September 15, 2018, the Convertible Notes will be convertible only upon the occurrence of certain events and during certain periods, and thereafter, at any time until the second scheduled trading day immediately preceding the maturity date. The Company further stated that on or after December 15, 2016, it may from time to time redeem for cash all or part of the Convertible Notes in certain circumstances. The Full Research Report on Endologix Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2f8d_ELGX Healthways Inc. Research Report On December 5, 2013, Healthways Inc. (Healthways) announced that the Company and SulAmérica, independent health insurer in Brazil, have signed a new five-year agreement to launch Latin America's most comprehensive private health and well-being improvement program for helping SulAmérica's 2 million members make sustained lifestyle changes while reducing overall healthcare costs. The Company stated that under the terms of this new agreement, Healthways and SulAmérica will launch programs in 2014 for helping SulAmérica members understand their unique well-being scores, then subsequently address opportunities for improvement through personalized plans and tailored programs as the five-year agreement progresses. The Full Research Report on Healthways Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/76fd_HWAY EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, +1-310-496-8071 (North America)
Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals,
Press spacebar to pause and continue. Press esc to stop.